1. Bispecific T Cell Engagers for the Treatment of Multiple Myeloma: Achievements and Challenges
- Author
-
Kinan Alhallak, Hannah Bash, Ola Adebayo, Abdel Kareem Azab, Jessica Yavner, Ayah Khaskiah, Amanda Jeske, Chaelee Park, Jennifer Sun, and Berit Lubben
- Subjects
0301 basic medicine ,Oncology ,Cancer Research ,medicine.medical_specialty ,medicine.medical_treatment ,T cell ,Review ,bispecific T cell engagers ,03 medical and health sciences ,0302 clinical medicine ,Internal medicine ,medicine ,RC254-282 ,Multiple myeloma ,business.industry ,Neoplasms. Tumors. Oncology. Including cancer and carcinogens ,chimeric antigen receptor-T cells ,Immunotherapy ,medicine.disease ,Review article ,multiple myeloma ,030104 developmental biology ,medicine.anatomical_structure ,Hematological malignancy ,Novel agents ,030220 oncology & carcinogenesis ,business - Abstract
Simple Summary Here we list the benefits and disadvantages of using bispecific T cell engagers (BTCEs) for the treatment of multiple myeloma (MM). We summarize the mechanism of action; the various targets used for BTCE therapy for MM such as BCMA, CD38, FcRH5, CD19, and CD138; and novel strategies used to circumvent the limitations of BTCE therapy. Abstract MM is the second most common hematological malignancy and represents approximately 20% of deaths from hematopoietic cancers. The advent of novel agents has changed the therapeutic landscape of MM treatment; however, MM remains incurable. T cell-based immunotherapy such as BTCEs is a promising modality for the treatment of MM. This review article discusses the advancements and future directions of BTCE treatments for MM.
- Published
- 2021
- Full Text
- View/download PDF